Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hang Lee, Ph.D.

Co-Author

This page shows the publications co-authored by Hang Lee and Ursula Matulonis.
Connection Strength

1.865
  1. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
    View in: PubMed
    Score: 0.167
  2. Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
    View in: PubMed
    Score: 0.158
  3. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
    View in: PubMed
    Score: 0.154
  4. Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
    View in: PubMed
    Score: 0.141
  5. Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010; 28(5):451-69.
    View in: PubMed
    Score: 0.121
  6. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
    Score: 0.119
  7. Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
    View in: PubMed
    Score: 0.119
  8. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
    View in: PubMed
    Score: 0.116
  9. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
    View in: PubMed
    Score: 0.112
  10. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
    Score: 0.112
  11. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1183-93.
    View in: PubMed
    Score: 0.106
  12. Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
    View in: PubMed
    Score: 0.095
  13. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
    View in: PubMed
    Score: 0.079
  14. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229.
    View in: PubMed
    Score: 0.057
  15. Lu W, Matulonis UA, Dunn JE, Lee H, Doherty-Gilman A, Dean-Clower E, Goodman A, Davis RB, Buring J, Wayne P, Rosenthal DS, Penson RT. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 12; 24(4):233-240.
    View in: PubMed
    Score: 0.037
  16. Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72.
    View in: PubMed
    Score: 0.030
  17. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
    View in: PubMed
    Score: 0.030
  18. Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009 Jul; 15(7):745-53.
    View in: PubMed
    Score: 0.029
  19. Lu W, Hu D, Dean-Clower E, Doherty-Gilman A, Legedza AT, Lee H, Matulonis U, Rosenthal DS. Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. J Soc Integr Oncol. 2007; 5(1):1-10.
    View in: PubMed
    Score: 0.025
  20. Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):427-35.
    View in: PubMed
    Score: 0.021
  21. Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
    View in: PubMed
    Score: 0.021
  22. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.